全文获取类型
收费全文 | 131655篇 |
免费 | 10146篇 |
国内免费 | 3583篇 |
专业分类
耳鼻咽喉 | 1035篇 |
儿科学 | 2489篇 |
妇产科学 | 1815篇 |
基础医学 | 8030篇 |
口腔科学 | 2887篇 |
临床医学 | 15745篇 |
内科学 | 19224篇 |
皮肤病学 | 2311篇 |
神经病学 | 9138篇 |
特种医学 | 4141篇 |
外国民族医学 | 39篇 |
外科学 | 12500篇 |
综合类 | 19129篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5735篇 |
眼科学 | 2038篇 |
药学 | 10572篇 |
79篇 | |
中国医学 | 11146篇 |
肿瘤学 | 17306篇 |
出版年
2024年 | 213篇 |
2023年 | 2309篇 |
2022年 | 3551篇 |
2021年 | 5958篇 |
2020年 | 5582篇 |
2019年 | 4980篇 |
2018年 | 4693篇 |
2017年 | 5287篇 |
2016年 | 5521篇 |
2015年 | 5187篇 |
2014年 | 9668篇 |
2013年 | 12086篇 |
2012年 | 7803篇 |
2011年 | 8366篇 |
2010年 | 6804篇 |
2009年 | 6285篇 |
2008年 | 6125篇 |
2007年 | 6527篇 |
2006年 | 5808篇 |
2005年 | 5118篇 |
2004年 | 4132篇 |
2003年 | 3740篇 |
2002年 | 3054篇 |
2001年 | 2690篇 |
2000年 | 2221篇 |
1999年 | 1741篇 |
1998年 | 1452篇 |
1997年 | 1213篇 |
1996年 | 1015篇 |
1995年 | 914篇 |
1994年 | 726篇 |
1993年 | 558篇 |
1992年 | 494篇 |
1991年 | 452篇 |
1990年 | 400篇 |
1989年 | 333篇 |
1988年 | 331篇 |
1987年 | 280篇 |
1986年 | 225篇 |
1985年 | 265篇 |
1984年 | 226篇 |
1983年 | 169篇 |
1982年 | 170篇 |
1981年 | 173篇 |
1980年 | 134篇 |
1979年 | 128篇 |
1978年 | 68篇 |
1977年 | 45篇 |
1976年 | 50篇 |
1975年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
21.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
22.
23.
《Obstetrics, Gynaecology and Reproductive Medicine》2020,30(6):175-183
Menopause is generally experienced as a biopsychosocial process involving physiological changes, and influenced by a wide range of psychological, social and cultural factors. The loss of ovarian oestrogen production may cause debilitating symptoms, including hot flushes, night sweats, sleep disturbance, vaginal dryness, dyspareunia, bladder dysfunction, loss of libido, and mood changes. Experience of the menopause transition varies widely between individuals, depending on the age of onset, personal health and wellbeing, social context, environment and culture.Hormone Replacement Therapy (HRT) remains the most effective treatment for the management of vasomotor symptoms and vaginal dryness, but has no proven role in the treatment of chronic diseases of ageing. Treatment should be individualized, and for most healthy women aged 50–59 years the risks of HRT are low. An understanding of the pathophysiology of menopausal symptoms and the risks and benefits of both hormonal and non-hormonal treatments assists in the individual management of patients. 相似文献
24.
25.
26.
《Sleep medicine》2020
ObjectivesPrior evidence suggests that sleep duration and sleep difficulties may be associated with cognitive function in old age, but little is known about the sleep–cognition association in late mid-life. Our aim was to examine the associations of accelerometer-based sleep duration as well as subjective sleep difficulties with different domains of cognitive function among aging workers.MethodsThe study population consisted of 289 participants (mean age 62.4 years, SD 1.02; 83% women) from the Finnish Retirement and Aging Study (FIREA). Sleep difficulties were measured using Jenkins Sleep Problem Scale (difficulties falling asleep, difficulties maintaining sleep, waking up too early in the morning, and nonrestorative sleep). Sleep duration was measured with wrist-worn accelerometer and self-report, and participants were divided into short (<7 h/night), mid-range (7–9 h/night) and long (≥9 h/night) sleepers. Participants underwent extensive cognitive testing covering three domains: (1) memory, (2) executive function, and (3) attention and information processing.ResultsGreater difficulties in waking up too early in the morning were associated with poorer executive function measured with Spatial Working Memory (SWM) test (p = 0.005). Additionally, nonrestorative sleep was associated with poorer executive function measured with Trail Making Test, B–A, (p = 0.036) and borderline significantly with lower SWM (p = 0.056). Compared to mid-range sleepers, long sleepers tended to have poorer cognitive function (all memory function tests and SWM), but the associations were not statistically significant due to small number of long sleepers.ConclusionsSubjective sleep difficulties may be linked to poorer executive function in a relatively healthy population of older workers in their 60 s. Thus, promoting good sleep quality may translate into better cognitive health in late mid-life. 相似文献
27.
目的观察脑电仿生电刺激小脑顶核对脑梗死后认知功能障碍的影响,并探讨其可能的机制。方法选取脑梗死后并发认知功能障碍患者50例,随机分成治疗组与对照组各25例。2组患者均接受康复治疗及认知功能训练,治疗组同时加用脑电仿生电刺激进行干预。2组患者分别于治疗前后应用蒙特利尔认知评估量表(MoCA)、简易精神状态量表(MMSE)评定认知功能变化,采用经颅多普勒超声(TCD)评估颅内动脉血流动力学改变。结果治疗后2组患者MoCA评分、MMSE评分均较组内治疗前提高(P<0.05),且治疗组评分明显较对照组高,差异有统计学意义(P<0.05)。治疗后2组患者颅内动脉血流动力学较组内治疗前改善(P<0.05),且治疗组较对照组改善更显著,差异有统计学意义(P<0.05)。治疗组与对照组总有效率分别为92%和64%,差异有统计学意义(P<0.05)。结论脑电仿生电刺激小脑顶核可有效改善脑梗死患者的认知功能,其可能机制是通过改善患者的脑循环进一步改善认知功能。 相似文献
28.
29.
30.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献